Furthermore, the heterologous combination of target antigen-expressing VSV-GP with the peptide vaccine KISIMA showed pre-clinical efficacy by strongly enhancing tumor-specific CD8+ T proportions and reshaping tumor immune infiltrating cell compositions in immunologically hot and cold tumors, and is currently being assessed in clinical phase I trials (NCT04046445, NCT05846516) [25,26]. Here, CD8A is linked to neoplasm.